Natera, Inc. (NASDAQ:NTRA) Position Decreased by US Bancorp DE

US Bancorp DE decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 11.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,326 shares of the medical research company’s stock after selling 1,085 shares during the period. US Bancorp DE’s holdings in Natera were worth $1,318,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Proficio Capital Partners LLC bought a new position in shares of Natera during the 4th quarter valued at about $16,113,000. GenTrust LLC bought a new position in shares of Natera during the 4th quarter valued at about $7,601,000. Whipplewood Advisors LLC bought a new position in shares of Natera during the 4th quarter valued at about $149,000. ARK Investment Management LLC boosted its position in shares of Natera by 29.1% during the 4th quarter. ARK Investment Management LLC now owns 887,711 shares of the medical research company’s stock valued at $140,525,000 after purchasing an additional 200,008 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd boosted its position in shares of Natera by 211.9% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 31,144 shares of the medical research company’s stock valued at $4,930,000 after purchasing an additional 21,160 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Activity

In other Natera news, CEO Steven Leonard Chapman sold 87,272 shares of Natera stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the sale, the chief executive officer now owns 203,354 shares in the company, valued at $29,160,963.60. The trade was a 30.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Solomon Moshkevich sold 6,000 shares of Natera stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total transaction of $859,740.00. Following the sale, the insider now owns 143,768 shares in the company, valued at $20,600,516.72. This represents a 4.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 301,571 shares of company stock valued at $48,322,810 over the last 90 days. 7.60% of the stock is currently owned by company insiders.

Natera Stock Performance

NTRA stock opened at $140.66 on Friday. The stock has a market cap of $19.02 billion, a P/E ratio of -79.92 and a beta of 1.80. The firm has a 50 day simple moving average of $165.61 and a 200 day simple moving average of $147.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Sanford C. Bernstein raised their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, January 10th. TD Cowen raised their target price on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Craig Hallum raised their target price on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Robert W. Baird raised their target price on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Finally, StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $173.56.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.